Finding · criterion S8

Who sells retatrutide, a drug still in phase 3 trials?

13 sellers in the ledger list retatrutide on their own pages, all of them research vendors. Retatrutide is an investigational drug: Eli Lilly has run 10 phase 3 trials of it, has not yet filed it for approval, and FDA states that it cannot be used in compounding.

The number, and where it comes from

A seller is counted here only where its own record lists retatrutide by name, read from its product pages, its own store data or a batch certificate it hosts. That is the list on who sells retatrutide, and it carries every record's eight dispositions. No telehealth service in the ledger lists retatrutide; every seller that does is a research vendor selling it for laboratory use.

Listed under a code, and not counted

5 more research vendors list a GIP, GLP-1 and glucagon agonist under a code such as GLP-3 or RT without printing the word retatrutide. The ledger does not count a molecule a seller will not name, so these records are listed here and not above.

• Pinnacle Peptides: GLP-1/GIP/GCG (RT), behind a request-access screen
• Bioscience Peptides: GLP-3 in 10, 30, 50 and 60 mg vials, whose certificate reads GLP RT
• Amino Club: GLP-3 (RT), 10 mg, behind a researcher attestation
• Xcel Peptides: GLP-3 (RT), behind a sign-in
• Onyx Research: GLP-3 RT, sold as a lyophilized peptide for in vitro use

3 research vendors show no catalog without an account or a password, so whether they sell retatrutide is not known: Modern Aminos, Simple Peptide, Regen Peptides.

What the drug is, on the regulator's and the maker's record

ClinicalTrials.gov lists 10 phase 3 studies of retatrutide sponsored by Eli Lilly and Company, 4 of them completed and the rest active and no longer recruiting.

Lilly's release of July 23, 2026 states its filing plan in its own words: Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027. Until that application is filed and approved, no retatrutide product is approved in the United States.

FDA's page on unapproved GLP-1 drugs states: Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition. It adds: FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled “for research purposes” or “not for human consumption.” These products have been sold directly to consumers for human use with dosing instructions.

Warning letters that name it

19 FDA warning letters issued from 2024 to 2026 contain the word retatrutide. 3 of them are filed in this ledger against the record each names: 695156, Prime Vitality, Inc. dba Prime Peptides, 695663, Swisschems, 694608, Xcel Research LLC. The others are addressed to companies that hold no record here.

• Issued August 24, 2026: 735067, TXP Innovations LLC dba Tex Peptides, 734884, Royal Peptides LLC, 733652, NuScience Peptides LLC, 735063, Peptide Partners LLC, 735127, Peak Performance Peptides
• Issued March 31, 2026: 721088, Lovega LLC dba Pink Pony Peptides, 721806, Gram Peptides, 721805, Prime Sciences, 721600, Mile High Compounds LLC
• Issued September 9, 2025: 715506, Amazing Meds, 713650, GenLabMeds, 712126, MedClub by Dr. Jenn, 715883, GLP-1 Solution, 716459, ASN-LABS, 715798, EA WORKS Limited Liability Company dba Trust Labs
• Issued December 10, 2024: 695156, Prime Vitality, Inc. dba Prime Peptides, 695663, Swisschems, 694608, Xcel Research LLC, 695607, Summit Research Peptides

The list covers every FDA warning letter from 2024 to September 2026 whose subject concerns unapproved drugs, 249 letters in all, each searched for the word retatrutide.

What this does not say

It does not say that any seller listed above breaks the law, and it does not say that the vials hold what the label states. A test report that passes S5 is a document about one lot sent to one laboratory. The piece records who lists the molecule, how each one labels it, and what the maker and the regulator have said, on the reading date at the head of the page.

Sources

• ClinicalTrials.gov, phase 3 studies of retatrutide
• Eli Lilly and Company, investor release of December 11, 2025
• Eli Lilly and Company, investor release of May 21, 2026
• Eli Lilly and Company, investor release of July 23, 2026
• FDA, concerns with unapproved GLP-1 drugs used for weight loss
• American Peptides, its own record
• Blue Sky Peptide, its own record
• Bluum Peptides, its own record
• Evolve Peptides, its own record
• Geo Peptides, its own record
• Nexus Peptides, its own record
• Northline Labs, its own record
• Prime Peptides, its own record
• PS Peptides, its own record
• Research 1 Peptides, its own record
• The Peptide Store, its own record
• True Peptides, its own record
• Umbrella Labs, its own record

Seller counts are computed from the ledger at build time against Standard v1.1. The trial, release and FDA rows were read in September 2026.

Counts are generated from the ledger at build time, so this page cannot drift from the records it summarizes. Method and null semantics: how checks are performed. This page ranks nothing, recommends nothing, and carries no partner link.

Related findings

All 15 findings →